Role of Long-Acting Injectable Second-Generation Antipsychotics in the Treatment of First-Episode Schizophrenia: A Clinical Perspective

Table 1

Survey of studies on LAI risperidone in first-episode schizophrenia patients.

Author, year	Study design	Duration of schizophrenia	N	Comparator	Result
Parellada et al., 2005 [39]	Six-month open study	Median one year, no more than 3 years	382	0	73% patients completed the study, statistically significant decrease of PANSS; 40% patients achieved at least 20% reduction of total PANSS score.
Malla et al., 2006 [44]	Two-year open study	Up to 3 years	15	Oral AP2G	More significant reduction of total PANSS score versus oral risperidone.
Emsley et al. 2009 [30]	Two-year open study	First episode	50	0	72% patients completed the study; 78% of them reached at least 50% reduction of symptoms; remission persisted for two years in 62% patients [42].